March 12, 2024 (v1)
Publication
Background: Serous chorioretinopathy has been associated with MEK inhibitors, including cobimetinib. We describe the clinical features of serous retinopathy observed with cobimetinib in patients with BRAFV600-mutated melanoma treated in the Phase III coBRIM study. Methods: In the coBRIM study, 493 patients were treated in two randomly...
Uploaded on: March 14, 2024